Despite the rapid diffusion of accountable care organizations (ACOs), the effect of ACO enrollment on cancer diagnosis, treatment, and survivorship remains unknown. The objective of this study was to determine whether Medicare Shared Savings Program (MSSP) ACO enrollment was associated with changes in screening for breast, colorectal, and prostate cancers.
INTRODUCTION
Accountable care organizations (ACOs) were developed to promote shared accountability for the cost and quality of care delivered to populations across the continuum of care settings. 1, 2 The Medicare Shared Savings Program (MSSP) is the largest US ACO program, currently comprising 435 ACOs caring for 9 million assigned Medicare beneficiaries. 3 The last 5 years have witnessed a marked diffusion of the ACO model, with the number of ACO-covered lives increasing from 2.7 million in 2011 to 28.3 million in 2016. 4 Evaluations of early Medicare ACOs reveal modest improvement in health care spending and quality. [5] [6] [7] [8] [9] Furthermore, evidence suggests that ACO enrollment may reduce the use of lowvalue health care services. 10 Cancer screening is a bidirectional measure of quality, with effective cancer screening programs balancing the predicted benefits of early cancer detection against the risks of diagnosis and downstream management of screendetected cancers. To this end, overscreening is considered the delivery of screening services to those at particular risk of other-cause mortality in whom the predicted benefit of early detection is thought to be small. Underscreening refers to withholding screening services from individuals in whom the predicted benefit of early detection outweighs the predicted downstream harms. Although screenings for breast and colorectal cancer are included as preventive care quality measures in the MSSP, prostate cancer is not included likely because of ongoing controversies surrounding the balance of benefit and harm associated with early prostate cancer detection. To date, there few data remain that characterize the relation between the use of cancer screening services and ACO participation and, more specifically, whether patterns of Cancer November 15, 2018 cancer screening differ among ACO and non-ACO populations. Because MSSP spending goals are defined using 3 years of benchmarked population spending, it stands to reason that ACOs engaging in significant overuse of discretionary health care at baseline are well positioned to reduce health care spending and, hence, achieve shared savings. Nonetheless, differences in cancer screening rates among ACO and non-ACO populations, to date, have not been reported.
There remain important unanswered questions surrounding the competing incentives for and against cancer screening in risk-bearing payment models. Specifically, the net effect of quality incentives that promote cancer screening, financial incentives that discourage screening, and downstream management of screen-detected cancers remains unknown. To this end, we sought to characterize the association between MSSP ACO enrollment and changes in the prevalence of breast, colorectal, and prostate cancer screening. We hypothesized that the prevalence of breast, colorectal, and prostate cancer screening would be higher among Medicare beneficiaries who were attributed to MSSP ACOs at baseline. Furthermore, we hypothesized that ACO enrollment would result in an increase in breast and colorectal cancer screenings among ACO-attributed beneficiaries relative to non-ACO controls and would result in a relative reduction in prostate cancer screening.
MATERIALS AND METHODS

Study Population
To build our cohort, we used Medicare enrollment and claims data from 2006 through 2014 to include every beneficiary in the Centers for Medicare & Medicaid Services (CMS) Shared Savings beneficiary file in addition to a 20% random sample of non-ACO beneficiaries. The cohort was restricted to those aged >65 years who were continuously enrolled in Parts A and B. In the event of death, the beneficiary was followed through the end of the last full calendar year for analysis. This study was approved by the Vanderbilt University Medical Center Institutional Review Board.
ACO Attribution
Each beneficiary was attributed yearly from 2007 through 2014 to an ACO or non-ACO provider using data from the CMS ACO Provider File and claims for qualified primary care services according to the CMS MSSP attribution rules. 11 Beneficiaries were assigned on a yearly basis to the primary care provider who delivered the most allowed charges for CMS-qualified primary care services in a specific evaluation year. If a beneficiary did not receive any qualified service from a primary care provider in a specific year, then she was attributed to the specialist provider who billed for the plurality of qualified services. Beneficiaries attributed to ACO providers were considered the ACO treatment group, and beneficiaries attributed to non-ACO providers were considered the control group. We limited our analytic sample to beneficiaries who received at least 1 qualified primary care service in any evaluation year to minimize bias associated with default non-ACO assignment in individuals who did not receive qualified services.
Individuals attributed to an ACO had 1 of 3 staggered MSSP contract start dates (April 1, 2012; July 1, 2012; or January 1, 2013), and ACO beneficiaries were given an ACO start date associated with their particular MSSP contract. Control beneficiaries were randomly assigned 1 of the 3 MSSP start dates according to the distribution of start dates of the ACO group within the same hospital referral region (HRR). Each HRR represents a health care market for tertiary medical care, as defined using Medicare claims. 12 Each beneficiary's start date was considered the beginning of the ACO period, and time intervals were measured annually.
Identification of Cancer Screening
We identified services for breast, colorectal, and prostate cancer screenings using inpatient, outpatient, and carrier claims. For all measures of cancer screening, we developed both sensitive and specific algorithms to characterize screening services. We did so because of concerns surrounding the ability of claims to distinguish between screening and diagnostic services.
Prostate cancer
We identified all claims for prostate-specific antigen (PSA) testing and adapted previously published methods 13 to distinguish screening from diagnostic PSA testing. We excluded all PSA tests performed after a diagnosis of prostate cancer and any PSA tests performed within 90 days of a prior PSA. For our specific definition, we excluded PSA tests performed within 180 days of a diagnosis of prostatitis, hematuria, urinary obstruction, or other disorder of the prostate.
Breast cancer
Breast cancer screening was identified using claims for mammography, adapting previously published work by Smith-Bindman and colleagues.
14 After identifying all mammography claims for beneficiaries in our study cohort, we excluded services performed after a breast cancer
Cancer November 15, 2018 diagnosis. Of those remaining, we retained those billed with a Healthcare Common Procedure Coding System code indicating screening; for claims that were billed as diagnostic, we retained those that were at least 1 year after any prior breast procedures or that were not followed by a subsequent diagnosis of breast cancer for at least 6 months. Our sensitive definition removed the first step in the algorithm of Smith-Bindman et al requiring that no mammogram had been performed within the prior 9 months. Our specific definition included this restriction.
Colorectal cancer
Colorectal cancer screening included claims for colonoscopy, sigmoidoscopy, fecal occult blood testing, and double-contrast barium enema. Adapting previously published work to characterize colorectal cancer screening, 15, 16 we excluded any claims performed after a diagnosis of colorectal cancer or colectomy. For our sensitive definition, we removed claims that were within 3 years of a prior colonoscopy, 4 years of a prior sigmoidoscopy or double-contrast barium enema, or 8 months of a prior fecal occult blood test. Our specific definition included a lengthier interval between colonoscopy claims to 8 years. In both samples, we then excluded claims for colorectal screening services that followed 15 to 61 days after a diagnosis, such as colorectal polyp or abdominal pain, suggesting a diagnostic procedure. We applied the 15-day floor to allow for billing lags and to ensure this exclusion applied to procedures that were ordered as diagnostic subsequent to another diagnosis and that were not part of a routine battery of screening examinations that subsequently led to a diagnosis.
Covariates
We included age, sex, race or ethnicity, dual Medicaid eligibility of our study population, and end-stage renal disease status from the Medicare Master Beneficiary Summary Files. We evaluated 27 chronic condition indicators from the Chronic Conditions Data Warehouse and developed a count of chronic conditions per beneficiary. In addition, we included zip code-level sociodemographic characteristics from the US Census, including the percentage of population below the federal poverty line, the percentage without a high school degree, the percentage enrolled in Medicare, and household median income.
Analysis
Our precontract period was defined as 5 years before the ACO contract start date, excluding an implementation year immediately before the ACO contract start date. Our postcontract period was defined as 1 year after the contract start date. We excluded the year immediately preceding the contract start date a priori because of predicted anticipatory changes in clinical practice in preparation for financial risk. Binary and categorical characteristics are stated as proportions, and continuous characteristics are presented as means and standard errors.
For each of our outcomes, we performed difference-in-differences (DD) analyses using linear regression to characterize changes in annual screening rates after ACO enrollment compared with before enrollment in the ACO group relative to contemporaneous changes in the non-ACO control group. Unadjusted rates of breast, colorectal, and prostate cancer screening were observed graphically over the course of the study period. Visual inspection of preintervention trends confirmed the DD parallel trends assumption. For analyses of prostate and breast cancer screening, our precontract period included 5 years before ACO implementation. For colorectal cancer screening, however, we used a shorter precontract period of 2 indexed years before ACO implementation to capture steady baseline screening rates. We limited this shorter precontract period to account for the lengthy interval recommended between colonoscopy events and limitations surrounding identification of colorectal cancer screening events before Medicare enrollment. We present DD coefficients from models that included all covariates described above and included fixed effects for each HRR in each year and robust standard errors to account for clustering at the HRR level. We compare DD estimates versus mean screening rates in the ACO group in the precontract period to demonstrate the change in screening rates attributable to ACO care in the postcontract period relative to the precontract mean.
RESULTS
Our analysis includes a total of 56,470,997 person-years of observation, with 13,460,768 person-years of data among ACO beneficiaries and 43,010,199 person-years of data among non-ACO beneficiaries. We observed few differences in baseline characteristics between ACO and non-ACO beneficiaries. Furthermore, the observed differential changes in beneficiary-level and community-level baseline characteristics from pre-ACO to post-ACO enrollment were consistently of small magnitude ( Table 1) .
The rate of breast, colorectal, and prostate cancer screening was uniformly higher among Medicare
Cancer November 15, 2018 beneficiaries who were attributed to ACO providers versus non-ACO providers in the precontract period using both sensitive (Fig. 1, Table 2 ) and specific (Fig. 2,  Table 2 ) definitions of screening. Specifically, the mean precontract breast cancer screening rate among women attributed to ACO providers was 42.7% compared with 37.3% among women attributed to non-ACO providers (P < .0001). The mean precontract colorectal cancer screening rate was 10.1% among beneficiaries attributed to ACO providers and 9.2% among those attributed to non-ACO providers (P < .0001). Finally, the mean precontract prostate cancer screening rate was 35.1% and 31.3% among men attributed to ACO and non-ACO providers, respectively (P < .0001).
Next, we characterized the association between ACO enrollment and breast, colorectal, and prostate cancer screening. We observed that breast cancer screening rates were declining among women, which was attributed to both ACO and non-ACO providers in the precontract period (Fig. 1, left) . Implementing the sensitive definition of screening, ACO enrollment was associated with an absolute differential change (DD) of −0.79% (P < .0001), corresponding to a 1.8% relative reduction in breast cancer screening compared with pre-ACO baseline. Colorectal cancer screening rates were relatively stable during the precontract period (Fig. 1,  right) . MSSP ACO enrollment resulted in an absolute differential change (DD) of 0.24% (P = .0259), corresponding to a relative increase of 2.4% in colorectal cancer screening. Finally, the prevalence of PSA screening rapidly declined during the precontract period among beneficiaries attributed to both ACO and non-ACO providers. ACO enrollment, however, was associated with an absolute differential change (DD) of −1.20% (P = .0004), corresponding to a 3.4% relative reduction in PSA screening among ACO-enrolled men compared with contemporaneous changes among men not enrolled in MSSP ACOs. Similar results were obtained when we used specific definitions of breast, colorectal, and prostate cancer screening (Table 3) .
DISCUSSION
The objective of the current study was to characterize the effect of MSSP ACO enrollment on changes in breast, colorectal, and prostate cancer screening. We observed that, before ACO enrollment, screening was more common among Medicare beneficiaries attributed to ACO providers compared with those attributed to non-ACO providers. ACO enrollment was associated with small-magnitude reductions in the prevalence of breast and prostate cancer screening and a small increase in the prevalence of colorectal cancer screening. These data suggest that ACO enrollment does not have a large effect on breast, colorectal, or prostate cancer screening rates. Nonetheless, given the Cancer November 15, 2018 significant prevalence of screening in the Medicare population, the observed small differences ultimately may map to meaningful changes in the epidemiology of screen-detected cancers in the elderly US population. Early cancer detection is an essential component of preventive care, and both breast and colorectal cancer screenings are recommended for specific populations. 17, 18 Most professional organizations, including the US Preventive Services Task Force, advocate for shared decision making to determine whether individual men should engage in prostate cancer screening. [19] [20] [21] Improvement in the quality of cancer screening programs may be achieved through targeting screening services to those who stand to benefit from early detection and withholding screening from those who do not. Early evaluations of both the MSSP and Pioneer ACO programs have identified few significant changes in screening practices. McWilliams and colleagues reported no significant differential change in breast cancer screening among female ACO beneficiaries 6 and similar findings among beneficiaries attributed to Pioneer ACOs. 7 Others have reported small-magnitude reductions in low-value cancer screening associated with Pioneer ACO enrollment. 10 Although breast and colorectal cancer screening rates are included as MSSP preventive care performance measures, prostate cancer screening is not. Given the relation between quality performance and eligibility for shared savings, it stands to reason that ACO-enrolled providers are incentivized to optimize quality performance by screening for breast and colorectal cancers. However, it is interesting to note that we observed a significant differential reduction in breast cancer screening and a significant, small-magnitude increase in colorectal screening after ACO enrollment. The differential reduction in breast cancer screening, in fact, may reflect 
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Prostate Cancer November 15, 2018 reductions in overscreening as opposed to improvements in underscreening. Indeed, there is evidence to suggest significant rates of breast cancer overscreening 22 among fee-for-service Medicare beneficiaries, and this overscreening may be a target for value improvement in Medicare ACOs. We observed significantly higher prevalence of breast, colorectal, and prostate cancer screening in the precontract period among beneficiaries attributed to ACO providers compared with non-ACO providers. Differences in the prevalence of cancer screening between ACO and non-ACO beneficiaries may be ascribed to differences among the providers upon whom ACO attribution is based, differences in individual beneficiaries with respect to preferences for or against early cancer detection, or a combination of both. Certainly, these findings do suggest that there are unmeasured differences between ACO and non-ACO populations that merit consideration when evaluating both ACO performance and the downstream implications of ACO effects. Indeed, provider organizations with room to improve may be suited best to participate in ACO programs, at least in the short-term, because of the use of an own-ACO benchmark to define target population-level spending and, ultimately, financial performance. Indeed, there is evidence to suggest that ACOs with higher levels of baseline spending achieve higher levels of shared savings, presumably because of reductions in the use of discretionary services 23 that likely include cancer screening. There is no consensus surrounding the balance of risk and benefit associated with prostate cancer screening. Therefore, prostate cancer screening is not included as a performance measure in the MSSP. Given the downstream costs of screening, including services related to Cancer November 15, 2018 diagnosis, treatment, and survivorship, prostate cancer screening would be an expected target of ACO-level programs to reduce the provision of avoidable health care services. We observed absolute reductions in prostate cancer screening over the course of the study period among both ACO and non-ACO populations. Indeed, the magnitude of downward secular trends we observed among both ACO and non-ACO populations was far greater than the small ACO effect. Nonetheless, the observed differential reduction in prostate cancer screening was in excess of 3% greater among individuals attributed to MSSP ACOs compared with non-ACO controls.
Although it may not be surprising, our findings underscore the myriad potential challenges associated with delivering patient-centered care under the cloud of financial incentives perpetuated in risk-bearing payment models. Nearly all current prostate cancer screening guidelines recommend shared decision making (weighing the predicted individual benefits and harms of screening) to formulate individual screening decisions. There remains no optimal rate of population-level prostate cancer screening, and work must be done to benchmark screening rates in diverse populations to better define appropriate and inappropriate variation in rates of prostate cancer screening. Doing so will minimize the risk of de-implementation of shared decision making, a potential unintended consequence of financial accountability. This is of particular concern for African American men, who are known to harbor an increased risk of prostate cancer mortality. 24 There are several limitations to the current study that merit consideration. First, this study characterizes MSSP performance, and the extent to which these findings are generalizable to non-Medicare ACO programs remains unknown. Second, although ACO and non-ACO populations appear to be balanced, the voluntary nature of MSSP enrollment raises the possibility of unmeasured confounding secondary to selection. Third, our claimsbased cancer screening measures are subject to misclassification, although any misclassification is the same between ACO and non-ACO groups and across time. To mitigate this concern, we include analyses using 2 definitions of cancer screening with consistent results. Finally, the use of claims data precludes an evaluation of patient preference, which is a critical element of clinical decision making, particularly in the context of cancer screening.
Our findings provide evidence of dynamic changes in the prevalence guideline-concordant and discretionary cancer screening services after ACO enrollment.
